Physician profile
David Berken
NPI 1790105153
$32,518.04
in general payments reported to CMS, 2019-2025
34 companies · $4,759 in 2025
The $4,759 reported for 2025 was more than what 82% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,424 · 2020: $11K · 2021: $1,606 · 2022: $3,423 · 2023: $3,107 · 2024: $4,855 · 2025: $4,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,513.62 |
| Travel and Lodging | $1,206.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $16,355.45 | 2019-2025 | Infinity, Mako, Prostep Mica |
| Arthrex, INC. | $12,688.17 | 2019-2025 | Arthrex |
| Midsouth Orthopedics INC. | $1,317.86 | 2019-2022 | |
| Medinc of Texas | $572.92 | 2020 | |
| Amgen INC. | $186.64 | 2023-2025 | Evenity, Prolia, Prolia |
| Axogen | $165.66 | 2019-2023 | Avance Nerve Graft |
| Medical Device Business Services, INC. | $124.47 | 2019 | |
| Kerecis Limited | $123.73 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Curonix LLC | $104.84 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Wright Medical Technology, INC. | $99.65 | 2020 | |
| Convatec INC. | $73.89 | 2025 | |
| Vericel Corporation | $64.00 | 2019 | |
| Boston Scientific Corporation | $62.58 | 2023-2024 | Avvigo Guidance System, Wavewriter Alpha Prime 16 |
| Osteocentric Technologies, INC. | $56.88 | 2020 | |
| Solventum Corporation | $50.21 | 2024-2025 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $41.06 | 2024-2025 | Irrisept |
| Nalu Medical, INC. | $39.20 | 2025 | Nalu Neurostimulation System |
| Dynasplint Systems INC. | $37.50 | 2023 | Dynasplint |
| Pacira Therapeutics, INC. | $36.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $33.63 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $29.02 | 2021-2022 | |
| Medtronic USA, INC. | $28.92 | 2019 | |
| Sanara Medtech INC. | $27.94 | 2022 | |
| Abbott Laboratories | $22.71 | 2025 | Eterna |
| Horizon Therapeutics Plc | $20.70 | 2021 | |
| Depuy Synthes Sales INC. | $20.38 | 2023 | Na, Motoband, Tfn-Advance |
| Sanofi-Aventis U.S. LLC | $19.33 | 2020 | |
| Nevro Corp. | $19.13 | 2022 | |
| Bioventus LLC | $18.51 | 2024 | Exogen Ultrasound Bone Healing System |
| Ethicon US, LLC | $17.08 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.99 | 2023 | Zilretta, Iovera, Exparel |
| Kci USA, INC. | $15.04 | 2023 | Prevena |
| Treace Medical Concepts, INC. | $14.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.